Repository logo
 

Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies.

Accepted version
Peer-reviewed

Repository DOI


Change log

Authors

Taylor, Craig J 
Kosmoliaptsis, Vasilis  ORCID logo  https://orcid.org/0000-0001-7298-1387
Martin, Jessie 
Knighton, Graham 
Mallon, Dermot 

Abstract

BACKGROUND: Solid-phase assays to distinguish complement binding from noncomplement binding HLA-specific antibodies have been introduced, but technical limitations may compromise their interpretation. We have examined the extent to which C1q-binding to HLA-class I single-antigen beads (SAB) is influenced by denatured HLA on SAB, antibody titre, and complement interference that causes a misleading low assessment of HLA-specific antibody levels. METHODS: Sera from 25 highly sensitized patients were tested using Luminex IgG-SAB and C1q-SAB assays. Sera were tested undiluted, at 1:20 dilution to detect high-level IgG, and after ethylene diamine tetraacetic acid treatment to obviate complement interference. Conformational HLA and denatured HLA protein levels on SAB were determined using W6/32 and HC-10 monoclonal antibodies, respectively. Denatured HLA was expressed as HC-10 binding to untreated SAB as a percentage of maximal binding to acid-treated SAB. RESULTS: For undiluted sera, Luminex mean fluorescence intensity (MFI) values for IgG-SAB and C1q-SAB correlated poorly (r = 0.42). ethylene diamine tetraacetic acid and serum dilution improved the correlation (r = 0.57 and 0.77, respectively). Increasing levels of denatured HLA interfered with the detection of C1q binding. Consequently, the correlation between IgG-SAB MFI and C1q-SAB MFI was lowest using undiluted sera and SAB with greater than 30% denatured HLA (r = 0.40) and highest using diluted sera and SAB with 30% or less denatured HLA (r = 0.86). CONCLUSIONS: Antibody level, complement interference, and denatured HLA class I on SAB may all affect the clinical interpretation of the C1q-SAB assay. The C1q-SAB assay represents a substantial additional cost for routine clinical use, and we question its justification given the potential uncertainty about its interpretation.

Description

Keywords

Adult, Antibody Specificity, Complement Activation, Complement C1q, Female, Graft Rejection, Graft Survival, HLA Antigens, Histocompatibility, Histocompatibility Testing, Humans, Immunoglobulin G, Isoantibodies, Male, Middle Aged, Predictive Value of Tests, Protein Binding, Protein Denaturation, Protein Folding, Reproducibility of Results, Young Adult

Journal Title

Transplantation

Conference Name

Journal ISSN

0041-1337
1534-6080

Volume Title

Publisher

Ovid Technologies (Wolters Kluwer Health)
Sponsorship
This study was supported by the Cambridge National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge in collaboration with Newcastle University and in partnership with NHS Blood and Transplant (NHSBT). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or NHSBT. VK was supported by the Academy of Medical Sciences and the Evelyn Trust.